Sandego.net – In eastern Congo, where a rapidly spreading Ebola outbreak has become the country’s deadliest, more than 250 people have joined a study examining whether an experimental antiviral pill can prevent infection after exposure to the virus.

The trial centers on obeldesivir, a drug developed by Gilead that is being tested against the Bundibugyo strain of Ebola. This virus is driving the current outbreak and has no approved vaccine or treatment specifically designed for it. Researchers began the study in July as health authorities and medical teams seek new ways to contain an emergency that has already reached seven provinces.…